Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProStrakan Group has received additional key marketing authorizations for droperidol in a number of European countries, in particular in Germany and the UK. The company plans to launch the product in Germany in second half of 2008.
Subscribe to our email newsletter
Droperidol (to be branded Xomolix) is a injectable drug, indicated for the prevention and treatment of post-operative nausea and vomiting in adults and, as a second line, in children. It is also indicated for the prevention of nausea and vomiting induced by morphine derivatives during post-operative patient controlled analgesia in adults.
Wilson Totten, ProStrakan’s CEO, said: “The roll-out of Xomolix across Europe further extends ProStrakan’s pan-EU portfolio of products and, importantly, means that we can make this product available in additional countries where we know there to be a substantial level of unsatisfied patient need.”